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Chikungunya VLP: Background
 Chikungunya virus (ChikV) 
 Alphavirus (family Togaviridae)
 Infection characterized by rash, high fever and severe, chronic arthritis
 Endemic in Africa and parts of southeast Asia (Thailand, Indonesia, 
Philippines)





 Viral proteins E1, E2 and capsid (C)
 E1 and E2 ~ 50kD each
 E1/E2 for heterodimers
 Heterodimers form trimers
 C ~ 30kD
 240 copies of each protein/VLP
 Protein MW ~ 31,200,000
 Additional lipid membrane
 Spontaneously assembled particles similar to 
Chikungunya virus in morphology
Capsid E3 E2 6K E1
Alphavirus Genome:
nsP1 nsP2 nsP3 nsP4 Capsid E3 E2 6K E1
Proteins: Nonstructural Structural
CHIKV VLP
Cryo EM of VLP:
Ref:  Akahata, et al., 2010.  A virus-like particle vaccine for epidemic 
Chikungunya virus protects nonhuman primates against infection.  
Nature Medicine 16 (3): 334-338.
Formulation:  Key Steps and Challenges
 Buffer Selection
 Screen GRAS buffer systems, single concentration, pH, tonicity
 Goal:  VLP solubility, stability, maintenance of functional conformation
 Excipient Screen
 Screen GRAS excipients at multiple concentrations




Generally Regarded As Safe
(FDA accepted safety profile in human subjects)
Buffer Screen (pH)
 Goal:  Determine the effects of pH on VLP structure and aggregation state.
Buffer exchange via dialysis resulted in precipitation of VLP product at pH 3-6; 
focused screen on pH 7 and 8 solutions.
 Buffer conditions




 20 mM phosphate buffer, pH 7, with 218 mM sucrose (DSP buffer)
 Analytical Techniques
 Far-UV Circular Dichroism (Secondary Structure)











































Aggregation onset occurs between 
45-50°C, with similar profiles 
observed at pH 7 and 8 (Stock 
sample is at pH7 with 218mM 
sucrose)
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Alteration in VLP in secondary 
structure occurs between 45-
50°C, with similar profiles observed 
at pH 7 and 8 (precipitated pH 6 
sample is shown for comparison)
Formulation: Excipient Screening
 Goal:   Improve stability of VLP through addition of GRAS excipients
 Buffer
 20 mM sodium phosphate, pH 7, ionic strength adjusted to 0.15 using 
NaCl
 Analytical Techniques
 UV-Vis Spectroscopy:  Monitor OD350nm at 50
oC (Near Tm) for 2 hours
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 Far-UV Circular Dichroism (Secondary Structure)
 Intrinisic Tryptophan Fluorescence (Tertiary Structure)
 Screen #1:  27 excipients, single concentration
 Screen #2:  6 top candidates, multiple concentrations
Excipient Screen #1
20 Excipients, High Concentration



















































27 Excipients, High Concentration




















































6 Excipients, 3 Concentrations/Excipient



















































Summary of Aggregation Inhibition (OD350nm)
Excipient Screens #1, #2, #3
Excipient % inhibition Excipient % inhibition
Dextrose 20% 97 Glutamic acid  0.15M 24
Sucrose 20% 90 Sorbitol 20% 23
Sodium citrate 0.2M 88 Glycine 0.3M 23
Mannitol 20% 85 Aspartic acid 0.15M 22
Dextran sulfate 0.003mM 85 Sucrose 5% 21
Trehalose 20% 83 Tween 20 0.1% 16
Lactose 20% 72 Mannitol 5% 13
Malic acid 0.1M 71 β-CD 5% 10
12
Sodium citrate 0.1M 71 Glycerol 10% 9
Malic acid 0.15M 70 α-CD 5% 6
Dextrose 10% 69 Lactic acid  0.15M 1
Trehalose 10% 57 γ-CD 5% -2
Sucrose 10% 47 Proline 0.3M -2
Trehalose 5% 39 Lysine 0.3M -4
Mannitol 10% 38 Dextran T70 0.003mM -13
Malic aicd 0.05M 37 Briji 35  0.1% -20
Sodium citrate 0.05M 35 Pluronic F-68  0.1% -21
Dextrose 5% 29 Tween 80 0.1% -31
Arginine  0.3M 27 Ascorbic acid 0.15M -1516
Human albumin 1% 26
Osmolarity
Problem:  The most promising formulations in terms of thermal stability and 
aggregation inhibition have higher osmolality than acceptable for injection, in part 




Average SDBuffer Excipient #1 Excipient #2
- - 252 0
10% trehalose - 523 4
13
20 mM sodium 
phosphate, 
I=0.15, pH 7.0
10% sucrose - 571 27
10% dextrose - 895 4
10% mannitol - 898 4
0.1 M Malic Acid - 482 2
0.1 M sodium citrate - 506 5
10% trehalose
0.1M malic acid 816 12
0.1M sodium citrate 859 21
10% sucrose
0.1M malic acid 834 8
0.1M sodium citrate 863 7
10% dextrose
0.1M malic acid 1145 18
0.1M sodium citrate 1172 3
Osmolarity
Question:  Can the stability of the VLP be increased with excipients alone, 
permitting reduction of the base buffer salts (Phosphate, NaCl) and the osmolarity?
Excipient [Conc]










0.05 383 35 166 54±4
0.1 506 71 297 100±1
0.15 637 - 423 90±4
14
0.2 758 88±15 524 96±1
0.25 896 - 666 107±13
Malic Acid
0.05 367 37 151 -1±33
0.1 482 71 277 79±4
0.15 596 70±8 396 93±11
0.2 762 - 488 90±1
0.25 891 - 643 114±28
Excipient addition permits removal of NaCl and reduction in Phosphate 
concentration, while inhibiting up to 100% of VLP aggregation with 
acceptable osmolarity
Formulation:  Summary
 Sucrose, Lactose, Trehalose, Mannitol, Malic Acid and Na Citrate 
demonstrated good inhibition of VLP aggregation and increased thermal 
stability.
 Combinations of Na Phosphate, Na Citrate/Malic Acid, and a sugar-based 
excipient resulted in synergistic stabilizing effects, although with 
unacceptably high osmolality with isotonic NaCl.
 Decreased Na Phosphate and NaCl increased the effectiveness of both Na 
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Citrate and Malic Acid to inhibit aggregation of VLPs.
 Na Citrate inhibited aggregation more effectively than Malic Acid at lower 
concentrations.
 A final formulation consisting of 10mM Na/K Phosphate, 25mM Na 
Citrate, and 218mM Sucrose was chosen to transfer to process scale-up.
Stability:  Key Steps and Challenges
 Accelerated Stability/ Forced Degradation
 Stability of product under chemical and environmental stress (e.g. low and high 
pH, oxidation, light exposure, agitation, freeze-thaw, extreme temperature)
 Goals:
 Identify product degradation pathways
 Identify stability indicating analytical methods
 Correlate physical degradation to functional performance
 Real-Time Stability
 Stability of product under real life physical conditions (12-24 months)
 Goal:  Estimate product shelf life
 Analytical Techniques
 Release Assays (focus on stability indicating if known)
 Characterization Assays (DSC, CD, DLS)
16
Forced Degradation:  Freeze-Thaw
 Sample:  1mL CHIKV VLP in 10mM Na Phosphate, 25mM Na Citrate, 218mM 
Sucrose, pH 7.2
 Multiple Freeze-Thaw studies using both rapid (ice/acetone) and slow (-80°C) 
freeze rates showed no VLP degradation over up to 10 freeze-thaw cycles.
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Real-time Stability
 On-going 12 month stability study at both clinical storage (-20°C and 2-8°C) and accelerated (25°C 
and 40°C)
 Stability maintained at -20°C and 2-8°C at 1 month, while degradation is observed at 25°C and 40°C.
 Alterations in both secondary (CD) and tertiary (Fluorescence) thermal profiles observed
55.0 55.0
Circular Dichroism                                                                    Fluorescence
18



















































 Stability maintained at -20°C and 2-8°C at 1 month, while degradation is observed at 25°C and 
40°C.






Differential Scanning Calorimetry                                        Dynamic Light Scattering
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 A stable, frozen formulation has been developed for ChikV VLP 
consisting of 10mM Na/K Phosphate, 25mM Na Citrate, and 
218mM Sucrose at pH 7.2 for use in Phase I clinical trials.
 ChikV VLP remains structurally and immunologically stable (data not 
shown) in the chosen formulation buffer for greater than 4 weeks. 
Longer term real-time stability studies of ChikV VLP are ongoing.
 Forced degradation studies show that ChikV is susceptible to 
accelerated temperature  induced degradation, but is resistant to 
freeze-thaw stress under the conditions tested.
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